Table 1.
Adverse events commonly associated with hypercalcemia summarized in patients treated with teriparatide 20 μg/day who had elevated (>10.6 mg/dl) 4–6 h postdose serum calcium in comparison with the overall cohort of patients in the teriparatide group
| Overall cohorta (n = 541) | Patientsa with serum Ca > 10.6 (n = 50) | |
|---|---|---|
| Neurological | ||
| Headache | 44 (8.1%) | 4 (8.0%) |
| Depression | 21 (3.9%) | 3 (6.0%) |
| Gastrointestinal | ||
| Abdominal pain | 48 (8.9%) | 6 (12.0%) |
| Pancreatitis | 1 (0.2%) | 1 (2.0%) |
| Nausea | 51 (9.4%) | 6 (12.0%) |
| Anorexia | 8 (1.5%) | 1 (2.0%) |
| Constipation | 32 (5.9%) | 6 (12.0%) |
| Vomiting | 19 (3.5%) | 3 (6.0%) |
| Peptic ulcer/gastritis | 8 (1.5%) | 2 (4.0%) |
| Cardiovascular | ||
| Arrhythmias | 9 (1.7%) | 1 (2.0%) |
| Hypertension | 41 (7.6%) | 4 (8.0%) |
a n (%)